Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mai M Abdelmoaty

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Neuroimmune Pharmacology and Therapeutics|May 15, 2025
Neuroprotective MushroomsMai M Abdelmoaty, Rana Kadry, R Lee Mosley, et al.
Cell & Bioscience|November 14, 2023
Clinical biomarkers for Lewy body diseasesMai M Abdelmoaty, Eugene Lu, Rana Kadry, et al.
Clinical and Translational Medicine|July 8, 2022
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's diseaseMai M Abdelmoaty, Jatin Machhi, Pravin Yeapuri, et al.
Translational Neurodegeneration|May 22, 2023
An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbersKatherine E Olson, Mai M Abdelmoaty, Krista L Namminga, et al.
Neuroimmune Pharmacology and Therapeutics|November 29, 2023
Immune senescence in aged APP/PS1 miceMai M Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
European Journal of Medicinal Chemistry|December 12, 2017
Synthesis, biological evaluation, and metabolic stability of phenazine derivatives as antibacterial agentsMaddeboina Krishnaiah, Nathalia Rodrigues de Almeida, Venkatareddy Udumula, et al.
Ebiomedicine|May 17, 2021
Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's diseaseKatherine E Olson, Krista L Namminga, Yaman Lu, et al.
Frontiers in Immunology|October 21, 2021
Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage InteractionsMai M Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Neuroimmune Pharmacology and Therapeutics|May 15, 2025
Neuroprotective MushroomsMai M Abdelmoaty, Rana Kadry, R Lee Mosley, et al.
Cell & Bioscience|November 14, 2023
Clinical biomarkers for Lewy body diseasesMai M Abdelmoaty, Eugene Lu, Rana Kadry, et al.
Clinical and Translational Medicine|July 8, 2022
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's diseaseMai M Abdelmoaty, Jatin Machhi, Pravin Yeapuri, et al.
Translational Neurodegeneration|May 22, 2023
An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbersKatherine E Olson, Mai M Abdelmoaty, Krista L Namminga, et al.
Neuroimmune Pharmacology and Therapeutics|November 29, 2023
Immune senescence in aged APP/PS1 miceMai M Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
European Journal of Medicinal Chemistry|December 12, 2017
Synthesis, biological evaluation, and metabolic stability of phenazine derivatives as antibacterial agentsMaddeboina Krishnaiah, Nathalia Rodrigues de Almeida, Venkatareddy Udumula, et al.
Ebiomedicine|May 17, 2021
Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's diseaseKatherine E Olson, Krista L Namminga, Yaman Lu, et al.
Frontiers in Immunology|October 21, 2021
Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage InteractionsMai M Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
Pageof 1